OBJECTIVE-To determine changes in gene expression in epicardial adipose tissue (EAT) associated with coronary atherosclerosis (CAD) and effects of pioglitazone therapy.
I
n patients with multiple risk factors for coronary atherosclerosis (CAD), including type 2 diabetes, interleukin (IL)-1b and other proinflammatory genes and proteins are higher in epicardial adipose tissue (EAT) than subcutaneous adipose tissue (SAT) from the same patients (1) or EAT from patients without CAD (2), whereas anti-inflammatory IL-10 is increased (2) and anti-inflammatory adiponectin is reduced (3) .The relative expression of pro-and anti-inflammatory mediators may determine whether EAT contributes in a harmful or protective paracrine manner to CAD (4), which might be therapeutically relevant (5) .
IL-1b is secreted by classically activated M1 macrophages, whereas antiinflammatory IL-1 receptor antagonist (IL-1Ra) and IL-10 are secreted by resident M2 or "alternatively activated" macrophages (6) . IL-1Ra inhibits binding of IL-1b to and activation of its target cell receptor (7). IL-1Ra was identified in human visceral abdominal fat (VAT) and SAT by Juge-Aubry et al. (8) . The balance between IL-1b and IL-1Ra (the IL-1Ra: IL-1b ratio) is considered to determine the severity of the chronic inflammatory disease (7), of which CAD is an example. Murine IL-1Ra gene knockout (9) and human IL-1Ra gene association studies (10) indicate an important role for IL-1Ra in atherosclerosis. To our knowledge, IL1-Ra has not been reported in EAT. The peroxisome proliferator-activated receptor-g (PPARg) mediates the antiinflammatory action of thiazolidinediones in macrophages (6) .
Our objectives were to determine inflammatory gene expression in EAT contiguous with CAD in patients with metabolic syndrome (MS) and type 2 diabetes and changes associated with pioglitazone therapy.
RESEARCH DESIGN AND METHODS-Control, MS, type 2 diabetic, and pioglitazone-treated type 2 diabetic patients' age, sex, and anthropometric features; metabolic characteristics; drug therapy; study exclusion criteria; fat sample acquisition; mRNA isolation and quantification by RT-PCR; and statistical methods were previously described by us (11, 12) . In the current study, additional control subjects (12 vs. 6) were included; insulin resistance was estimated by homeostasis model assessment-insulin resistance (HOMA-IR) (13) in control subjects and MS patients. At the time of open heart surgery, seven type 2 diabetic patients had been treated with an average dose of 25 mg/day pioglitazone (range 15-45) for an average of 24 months (range 4-60), based on patient recalls of duration of therapy. Gensini scores of angiographic epicardial coronary atherosclerosis (14) were measured and were significantly lower in control subjects (mean 1.6, range 0-10) than in MS subjects (mean 29.7, range 6-62), type 2 diabetic patients (mean 38.0, range 10-100), and type 2 diabetic patients receiving pioglitazone (mean 30.9, range 17-80). The local institutional review board approved the study, and all patients involved gave their informed consent. Figure 1B and C show that IL-1Ra and IL-10 mRNAs, respectively, were significantly higher in EAT from MS and type 2 diabetic than control patients, whereas PPARg was similar (Fig.  1D) . In anterior thoracic (sternal) SAT, only PPARg mRNA was lower in MS and type 2 diabetes. There was a trend for higher IL1-b in EAT that was not statistically significant (Fig. 1A) . However, IL-1b mRNA was significantly greater in EAT than in SAT when measured within patient groups. Thus, for control subjects, mean IL-1b DCp was 23.14 for EAT versus 24.73 for SAT (P = 0.003); for MS patients, mean IL-1b DCp was 23.44 for EAT versus 24.96 for SAT (P = 0.007), and, for type 2 diabetic patients, mean IL-1b DCp was 23.93 for EAT versus 25.90 for SAT (P = 0.02). Pioglitazone therapy in type 2 diabetic patients was associated with decreased expression of IL-1b, IL-1Ra, and IL-10 mRNA in EAT (Fig. 1A-C) as well as less IL-10 mRNA (Fig. 1C ) and greater PPARg (Fig. 1D ) in SAT. IL-1Ra and IL-10 mRNAs in EAT from MS and type 2 diabetes that were significantly different from control subjects ( Fig. 1) were tested in multiple factor covariate analyses for effects of age, weight, BMI, waist, fasting blood glucose, A1C, HOMA-IR, ACE inhibitors, angiotensin receptor blockers, statins, aspirin, and metformin. None of these variables had a significant impact on the effects arising from MS and type 2 diabetic patients versus control subjects, since these differences also persisted after multiple covariate analysis.
RESULTS-
CONCLUSIONS-In patients with MS and type 2 diabetes with severe CAD, increased IL-1Ra and IL-10 mRNAs and an upward IL-1b trend were observed in EAT, whereas the three mRNA levels were similar in SAT, highlighting depot-specific gene expression differences and confirming higher IL-10 (2) in EAT contiguous with CAD.
Macrophages are densely concentrated in EAT around lipid-filled coronary atherosclerotic plaques (5) . Although M1 and M2 macrophages have not been studied in EAT, our data suggested that increases in IL-1Ra and IL-10 expression in EAT might represent a protective mechanism mediated by M2 macrophages in response to activated M1 macrophages recruited possibly by "inside-to-outside" coronary signaling (1) . The expression of IL-1b was not significantly enhanced in EAT, although there was an upward trend. However, IL-1b expression was greater in EAT compared with SAT within MS, type 2 diabetic, and control patient groups, suggesting the possibility that the lack of difference in IL-1b expression in EAT between MS patients, type 2 diabetic patients, and control subjects may have been due to masking by its higher expression in control subjects.
Treatment with pioglitazone in type 2 diabetic patients was associated with reductions in expression of IL-1b, IL-1Ra, and IL-10 in EAT and with only IL-10 in SAT. In this context, rosiglitazone has been shown to directly inhibit phorbol myristate acetate-activated but not basal IL-1Ra release from human SAT explants in vitro (8) . Because pioglitazone suppresses macrophage-mediated adipose tissue inflammation and IL-1b (6), it can be hypothesized that during pioglitazone therapy, reduced IL1-Ra expression in EAT might have been an indirect consequence of reduced expression of IL-1b in EAT. Pioglitazone was also associated with a selective increase in PPAR-g mRNA in SAT but not EAT. In as much as EAT is visceral fat originating embryologically from VAT (4), this finding was consistent with the report of greater pioglitazone-mediated upregulation of PPARg transcripts in cultured human abdominal SAT preadipocytes than omental preadipocytes in vitro (15) .
In conclusion, augmentation of antiinflammatory IL-1Ra and IL-10 gene expression in EAT suggested a potentially beneficial role for these adipokines in a proinflammatory milieu contiguous with CAD. Treatment with pioglitazone in type 2 diabetic patients with CAD was associated with a reduction of proinflammatory and anti-inflammatory genes in EAT and a selective increase in PPARg in SAT.
